LVTX - LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference | Benzinga
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
Presentation Details
Format: Fireside Chat
Date: Tuesday, June 25, 2024
Time: 9:30 AM ET
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website ...